Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| VRDN | 8-K | neutral | 5/10 | Viridian Therapeutics reported Q1 2026 financial results, highlighting a net loss of $104.9M vs $86.9M a year ago, with | May 5, 2026 |
| MCRB | 8-K | bearish | 7/10 | Seres Therapeutics reported Q1 2026 financial results: net loss of $19.9M vs net income of $32.7M in Q1 2025 (which incl | May 5, 2026 |
| QTTB | 8-K | neutral | 4/10 | Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025, driven by lower R&D | May 5, 2026 |
| EDIT | 8-K | neutral | 4/10 | Editas Medicine reported Q1 2026 results with a net loss of $0.26 per share, narrower than the $0.92 loss in Q1 2025, dr | May 5, 2026 |
| PFE | 8-K | neutral | 4/10 | Pfizer reported Q1 2026 Adjusted diluted EPS of $0.75, beating the $0.72 consensus by 4.2%, on revenue of $14.45B, which | May 5, 2026 |
| BNTX | 6-K | bearish | 7/10 | BioNTech reported Q1 2026 results with total revenue of €118.1M, down 35% YoY from €182.8M, driven by a 50% decline in C | May 5, 2026 |
| BNTX | 6-K | mixed | 6/10 | BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY from €182.8M) and a net loss of €531.9M (vs. €415.8M loss a y | May 5, 2026 |
| BNTX | PRESS-RELEASE | mixed | 6/10 | BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY) and a GAAP net loss of €531.9M (diluted EPS -€2.10), which b | May 5, 2026 |
| SAFX | 425 | mixed | 5/10 | XCF Global filed a Rule 425 communication (structured as an 8-K) updating its investor presentation and providing a Q1 2 | May 5, 2026 |
| SAFX | 8-K | neutral | 2/10 | XCF Global, Inc. filed an 8-K on May 4, 2026, disclosing an updated investor presentation (Exhibit 99.1) under Regulatio | May 5, 2026 |
| IDXX | 8-K | bullish | 8/10 | IDEXX reported Q1 2026 revenue of $1.141B (+14% YoY) and GAAP EPS of $3.47 (+17% YoY), beating consensus estimates of $1 | May 5, 2026 |
| NTHI | 10-K/A | neutral | 3/10 | NeOnc Technologies Holdings filed Amendment No. 1 to its 2025 10-K solely to add Part III information (Items 10-14) that | May 5, 2026 |
| OCS | PRESS-RELEASE | neutral | 5/10 | Oculis presented DME AWARE Delphi study results at ARVO 2026, reinforcing unmet need for non-invasive early DME treatmen | May 5, 2026 |
| ALKS | CLUSTER | neutral | 2/10 | Two Alkermes insiders, the EVP/CLO and EVP R&D/Chief Medical Officer, sold a combined $368K in open-market stock over fo | May 4, 2026 |
| TRDA | CLUSTER | bearish | 5/10 | Two top executives at Entrada Therapeutics sold a combined $629K in open-market sales over a 7-day window, with Presiden | May 4, 2026 |
| NRIX | CLUSTER | neutral | 2/10 | Three NRIX insiders (CFO, CLO, CSO) sold a combined $231K in open-market sales, a trivial 0.014% of the company's $1.7B | May 4, 2026 |
| MPLT | 144 | neutral | 2/10 | Officer Christopher Kroeger filed Form 144 to sell 236,470 shares (~$7.3M) under a 10b5-1 plan adopted on 12/29/2025. Th | May 4, 2026 |
| NBTX | PRESS-RELEASE | neutral | 5/10 | Nanobiotix announced FDA acceptance of a protocol amendment to its pivotal NANORAY-312 study for JNJ-1900 (NBTXR3) in he | May 4, 2026 |
| EBS | CLUSTER | neutral | 2/10 | Three directors of Emergent BioSolutions sold a total of approximately $385K in open-market shares over two days, repres | May 4, 2026 |
| HOTH | 8-K | bearish | 8/10 | Hoth Therapeutics received a Nasdaq deficiency notice on April 30, 2026 for failing to maintain the $1.00 minimum bid pr | May 4, 2026 |
| MPLT | 144 | neutral | 3/10 | Officer Lillie James Woodruff filed a Form 144 to sell 52,428 shares of common stock valued at approximately $1.61M, all | May 4, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem filed the detailed final voting map from its April 29, 2026 Ordinary General Meeting. The filing is purely proce | May 4, 2026 |
| BHVN | 424B5 | bearish | 6/10 | Biohaven filed a prospectus supplement to sell up to $350 million of common shares in an at-the-market offering through | May 4, 2026 |
| KTTAW | 8-K | neutral | 2/10 | Pasithea Therapeutics appointed Dr. Kartik Krishnan as Chief Medical Officer effective May 1, 2026, and granted substant | May 4, 2026 |
| TLX | PRESS-RELEASE | bullish | 5/10 | Telix announced publication of exploratory Phase 3 ZIRCON data in European Urology showing TLX250-Px PET/CT is highly pr | May 4, 2026 |
| DYN | 144 | neutral | 2/10 | Atlas Venture Opportunity Fund I, L.P., a major venture investor, filed a Form 144 indicating intent to sell 2,466 share | May 4, 2026 |
| SXTC | 6-K | bearish | 7/10 | China SXT Pharmaceuticals raised $3.5M through a dilutive private placement of 3.5M shares and 3.5M warrants at $1.00 pe | May 4, 2026 |
| DYN | 144 | neutral | 2/10 | Atlas Venture Fund XI, L.P., a major shareholder, filed a Form 144 to sell 6,241 shares of Dyne Therapeutics common stoc | May 4, 2026 |
| DYN | 144 | neutral | 2/10 | Atlas Venture Associates XI, L.P. filed a Form 144 to sell 61 shares of Dyne Therapeutics, with an estimated market valu | May 4, 2026 |
| ABEO | DEFA14A | neutral | 2/10 | Abeona Therapeutics filed additional definitive proxy soliciting materials (DEFA14A) on May 4, 2026, likely supplementin | May 4, 2026 |